荷兰罕见出血性疾病女性中重度月经出血高患病率:RBiN研究回顾性数据
RBiN研究纳入荷兰6家血友病治疗中心的263例罕见出血性疾病患者,分析其中111例≥16岁女性的重度月经出血(HMB)情况。80%的女性报告HMB,纤维蛋白溶解性疾病患者(94%)高于凝血因子缺乏患者(74%)(P=0.011)。仅少数女性接受止血药物治疗,HMB症状出现后诊断延迟显著。
要点
- 111例罕见出血性疾病女性中80%(89/111)报告重度月经出血。
- 纤维蛋白溶解性疾病患者HMB患病率94%(33/35)高于凝血因子缺乏患者74%(56/76)(P=0.011)。
- 89例HMB女性中82%(73例)曾需治疗,激素治疗最常用(64例,88%),抗纤溶药较少(18例,25%)。
核心结论
- HMB在罕见出血性疾病女性中常见,轻度缺乏者亦常报告HMB,仅少数女性接受止血药物治疗,HMB症状出现后诊断延迟显著。
研究设计与样本
- RBiN研究为回顾性研究,纳入荷兰全部6家血友病治疗中心2017年10月至2019年11月的263例罕见出血性疾病患者,本分析研究其中111例≥16岁女性的数据。
主要发现
- 80%的女性(89/111)报告HMB,纤维蛋白溶解性疾病患者为94%(33/35),凝血因子缺乏患者为74%(56/76),两组比较P=0.011。
- 89例HMB女性中82%(n=73)曾需治疗,激素治疗最常用(n=64;88%),抗纤溶药处方较少(n=18;25%)。
- 月经初潮即出现HMB的女性(n=61;69%)中,罕见出血性疾病诊断中位年龄为28岁(IQR,14-41)。
关键数值与推荐
- 根据国际血栓与止血学会出血评估工具,HMB症状评分从0分(无/轻微)到4分(需医疗干预的严重症状),HMB定义为评分≥1分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heavy menstrual bleeding (HMB) is associated with a reduced quality of life and limitations in social and physical functioning. Data on HMB in women with rare bleeding disorders (RBDs), including coagulation factor deficiencies and fibrinolytic disorders, are scarce. OBJECTIVES: To analyze the prevalence, severity, and treatment of HMB in Dutch women with an RBD. METHODS: The Rare Bleeding Disorders in the Netherlands (RBiN) study included 263 patients with an RBD from all 6 hemophilia treatment centers (October 2017-November 2019). In this analysis, data of 111 women aged ≥16 years were studied. According to the International Society on Thrombosis and Haemostasis bleeding assessment tool, HMB symptoms were scored from 0 (no/trivial) to 4 (severe symptoms requiring medical intervention). HMB was defined as a score ≥1. Age at RBD diagnosis was extracted from patient files. RESULTS: HMB was reported by 80% of women (89/111) and was more prevalent in women with a fibrinolytic disorder (33/35; 94%) than in women with a coagulation factor deficiency (56/76; 74%) (P = .011). Of the 89 women with HMB, 82% (n = 73) ever required treatment. Multiple treatment modalities were frequently used, both in severe and mild deficiencies. Hormonal treatment was mostly used (n = 64; 88%), while antifibrinolytics were prescribed less frequently (n = 18; 25%). In women with HMB since menarche (n = 61; 69%), median age at RBD diagnosis was 28 years (IQR, 14-41). CONCLUSION: HMB is common in women with RBDs. Women with mild deficiencies also frequently reported HMB. Only a minority of women were treated with hemostatic agents. A significant diagnostic delay was observed after the onset of HMB symptoms.
引用
- Maas DPMSM, Saes JL, Blijlevens NMA, et al. High prevalence of heavy menstrual bleeding in women with rare bleeding disorders in the Netherlands: retrospective data from the RBiN study. J Thromb Haemost. 2023. PMID: 37517479. doi:10.1016/j.jtha.2023.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。